Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase
inhibitors
    22.
    发明授权
    Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors 失效
    双环4-芳烷基氨基嘧啶衍生物作为酪氨酸激酶抑制剂

    公开(公告)号:US6057326A

    公开(公告)日:2000-05-02

    申请号:US238

    申请日:1998-02-06

    CPC分类号: C07D473/34 C07D239/94

    摘要: Novel and known bicyclic 4-aralkylaminopyrimidine derivatives of formula (I) wherein A is a benzene or imidazole ring; B is a benzene, tetralin, indane or 2-oxindole ring R is (C.sub.1 -C.sub.4)perfluoroalkyl, phenyl, phenyl-(C.sub.1 -C.sub.4)alkyl, hydroxy-(C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy-(C.sub.1 -C.sub.4)alkyl, (C.sub.2 -C.sub.4)acyloxy-(C.sub.1 -C.sub.4)alkyl, halobenzoyloxy-(C.sub.1 -C.sub.4)alkyl, carboxy, carbamoyl, (C.sub.1 -C.sub.4)alkoxycarbonyl, cyano, (C.sub.1 -C.sub.4)alkylcarbonyl, carboxy-(C.sub.1 -C.sub.4)alkyl, carbamoyl-(C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxycarbonyl-(C.sub.1 -C.sub.4)alkyl, halo-(C.sub.1 -C.sub.4)alkyl, amino-(C.sub.1 -C.sub.4)alkyl, mono- or di-(C.sub.1 -C.sub.4)alkylamino-(C.sub.1 -C.sub.4)alkyl, sulfo-(C.sub.1 -C.sub.4)alkyl or sulfamido-(C.sub.1 -C.sub.4)alkyl; each of R.sub.1 and R.sub.2, which may be the same or different, is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen or --NR.sub.5 R.sub.6 in which each of R.sub.5 and R.sub.6, which may be the same or different, is H or C.sub.1 -C.sub.4 alkyl; each of R.sub.3 and R.sub.4, which may the same or different, is hydrogen, C.sub.1 -C.sub.4 alkyl, halogen, hydroxy, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkoxycarbonyl, nitro, cyano or CF.sub.3 ; and the pharmaceutically acceptable salts thereof, are tyrosine kinase inhibitors. ##STR1##

    摘要翻译: PCT No.PCT / EP97 / 02965 Sec。 371日期1998年2月6日 102(e)日期1998年2月6日PCT提交1997年6月3日PCT公布。 公开号WO97 / 49689 日期:1997年12月31日新知名的式(I)双环4-芳烷基氨基嘧啶衍生物,其中A是苯或咪唑环; B是苯,四氢化萘,茚满或2-羟基吲哚环R是(C1-C4)全氟烷基,苯基,苯基 - (C1-C4)烷基,羟基 - (C1-C4)烷基,(C1-C4)烷氧基 - C1-C4)烷基,(C2-C4)酰氧基 - (C1-C4)烷基,卤代苯甲酰氧基 - (C1-C4)烷基,羧基,氨基甲酰基,(C1-C4)烷氧基羰基,氰基,(C1-C4)烷基羰基, - (C 1 -C 4)烷基,氨基甲酰基 - (C 1 -C 4)烷基,(C 1 -C 4)烷氧基羰基 - (C 1 -C 4) - 或二 - (C 1 -C 4)烷基氨基 - (C 1 -C 4)烷基,磺基 - (C 1 -C 4)烷基或磺酰氨基 - (C 1 -C 4)烷基; R 1和R 2各自可以相同或不同,是氢,C 1 -C 4烷基,C 1 -C 4烷氧基,卤素或-NR 5 R 6,其中可以相同或不同的R 5和R 6各自为H或 C 1 -C 4烷基; R 3和R 4可以相同或不同,为氢,C 1 -C 4烷基,卤素,羟基,C 1 -C 4烷氧基,C 1 -C 4烷氧基羰基,硝基,氰基或CF 3; 及其药学上可接受的盐是酪氨酸激酶抑制剂。

    Aryl and heteroaryl purine compounds
    23.
    发明授权
    Aryl and heteroaryl purine compounds 失效
    芳基和杂芳基嘌呤化合物

    公开(公告)号:US5965563A

    公开(公告)日:1999-10-12

    申请号:US860717

    申请日:1997-07-14

    摘要: Novel bicyclic condensed pyrimidine compounds having general formula (I) ##STR1## wherein X is --CH.sub.2 --, --NH--(CH.sub.2).sub.n --, --O--(CH.sub.2).sub.n -- or --S--(CH.sub.2).sub.n -- in which n is zero or 1; A is a 4,5-fused imidazole ring N-substituted by R.sub.3 which is hydrogen, C.sub.1 -C.sub.4 alkyl or benzyl, or A is a 2,3-fused pyridine ring C-substituted by R.sub.4 which is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen or NR.sub.5 R.sub.6 in which each of R.sub.5 and R.sub.6 independently is H or C.sub.1 -C.sub.4 alkyl; B is a bicyclic ring chosen from tetralin, indane and 2-oxindole; each of R.sub.1 and R.sub.2 independently is hydrogen, C.sub.1 -C.sub.4 alkyl, halogen, hydroxy, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkoxycarbonyl, nitro, cyano or CF.sub.3 ; and the pharmaceutically acceptable salts thereof.

    摘要翻译: PCT No.PCT / EP96 / 04460 Sec。 371日期1997年7月14日 102(e)1997年7月14日PCT PCT 1996年10月14日PCT公布。 公开号WO97 / 18212 PCT 日期1997年5月22日具有通式(I)的新型双环稠合嘧啶化合物,其中X是-CH 2 - , - NH-(CH 2)n - , - O-(CH 2)n - 或-S-(CH 2)n - ,其中 n为零或1; A是由R 3取代的4,5-稠合咪唑环,其为氢,C 1 -C 4烷基或苄基,或A为被R 4取代的2,3-稠合吡啶环,其为氢,C 1 -C 4烷基 ,C 1 -C 4烷氧基,卤素或NR 5 R 6,其中R 5和R 6各自独立地为H或C 1 -C 4烷基; B是选自四氢化萘,二氢化茚和2-羟吲哚的双环; R 1和R 2各自独立地是氢,C 1 -C 4烷基,卤素,羟基,C 1 -C 4烷氧基,C 1 -C 4烷氧基羰基,硝基,氰基或CF 3; 及其药学上可接受的盐。